ストックスクリーナーアプリを入手
9.23
10.65%
-1.15
前日終値:
$10.38
開ける：
$9.97
24時間の取引高:
137.68K
Relative Volume:
1.23
時価総額：
$51.47M
収益：
-
当期純損益:
$-16.35M
株価収益率:
-3.0262
EPS:
-3.05
ネットキャッシュフロー:
$-11.88M
1週間 パフォーマンス:
-4.28%
1か月 パフォーマンス:
+77.34%
6か月 パフォーマンス:
+172.98%
1年 パフォーマンス:
+102.95%
1日の値動き範囲:
$8.80
$10.13
1週間の範囲:
$8.80
$11.11
52週間の値動き範囲:
$2.52
$12.37
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
9.27 | 57.63M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.13 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
844.40 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.43 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.73 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Liver Cirrhosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - The Globe and Mail
Lipocine’s PPD drug trial continues after positive safety review By Investing.com - Investing.com India
Lipocine’s PPD drug trial continues after positive safety review - Investing.com
Lipocine Advances Phase 3 Postpartum Depression Drug Trial - TipRanks
Lipocine Inc Reports Progress in Phase 3 Trial for PPD - TradingView — Track All Markets
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire
How Lipocine Inc. stock reacts to global recession fearsMarket Activity Report & High Accuracy Investment Entry Signals - ulpravda.ru
How Lipocine Inc. stock performs in stagflationTrade Risk Assessment & AI Forecasted Stock Moves - ulpravda.ru
How Lipocine Inc. stock benefits from strong dollarJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - ulpravda.ru
Why Lipocine Inc. stock is considered a top pickJuly 2025 Big Picture & Fast Gain Stock Tips - Улправда
Why Lipocine Inc. stock could benefit from AI revolutionTrade Performance Summary & Free Fast Gain Swing Trade Alerts - Улправда
What is the fair value of Lipocine Inc. stock nowBear Alert & Reliable Entry Point Trade Alerts - ulpravda.ru
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда
Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда
Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets
Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber
How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber
Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria
Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks
Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets
Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com
Lipocine Earnings Notes - Trefis
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting - Investing.com UK
EBIT per share of Lipocine Inc. – BOATS:LPCN - TradingView
Lipocine (LPCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lipocine Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
2.30%
3.20%
大文字化:
|
ボリューム (24 時間):